{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010415","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.539395+00:00","generated_at":"2026-05-17T19:31:26.727287+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"MetaVia extends Phase 1 DA-1726 48mg MAD cohort to 8 weeks; top-line data Q4 2025","bullets":["Extended 48 mg MAD cohort to 8 weeks from 4; first patient received fifth weekly dose.","Top-line data from the extended cohort expected in Q4 2025.","Prior 32 mg dose data: mean weight loss 4.3% by Day 26, early satiety in 83% of patients.","Waist circumference reduction of up to 3.9 inches by Day 33 at 32 mg dose.","DA-1726 is a dual GLP1R/GCGR agonist for obesity with a 3:1 balanced activation ratio."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010415","json":"https://secwatch.observer/filing/0001558370-25-010415.json","markdown":"https://secwatch.observer/filing/0001558370-25-010415.md","text":"https://secwatch.observer/filing/0001558370-25-010415.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837025010415/0001558370-25-010415-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837025010415/mtva-20250806x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:31:26.727287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}